| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 54% | $1,065,034,885 | 17,095,263 | Lin Bioscience International Ltd. | 31 Dec 2024 | |||
| Darwin Global Management, Ltd. | 7% | $294,187,537 | 2,617,094 | Darwin Global Management, Ltd. | 03 Dec 2025 | |||
| Lin Yu-Hsin | 7.1% | $142,484,461 | 2,287,070 | Yu-Hsin Lin | 31 Dec 2024 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (% of par) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 6,933 | $1,109,313 | +$828,103 | 15,996.01% | 3 |
| 2025 Q3 | 2,288,469 | $169,346,585 | +$162,953,207 | 7,400% | 34 |
| 2025 Q2 | 78,139 | $4,508,619 | -$5,101,966 | 5,770% | 18 |
| 2025 Q1 | 149,657 | $9,909,658 | -$8,038,751 | 6,622% | 18 |
| 2024 Q4 | 282,406 | $17,820,740 | +$12,809,959 | 6,310% | 21 |
| 2024 Q3 | 78,699 | $3,689,407 | -$4,872,726 | 4,688% | 15 |
| 2024 Q2 | 186,568 | $8,522,342 | +$5,980,161 | 4,568% | 11 |
| 2024 Q1 | 58,112 | $2,229,758 | -$4,083,463 | 3,837% | 11 |
| 2023 Q4 | 155,109 | $7,095,600 | +$3,531,143 | 4,575% | 17 |
| 2023 Q3 | 99,593 | $3,165,868 | -$26,250,075 | 3,184.93% | 7 |
| 2023 Q2 | 1,040,502 | $14,866,363 | +$2,374,158 | 1,429% | 6 |
| 2023 Q1 | 850,185 | $25,389,513 | -$211,069 | 2,989.98% | 8 |
| 2022 Q4 | 857,329 | $25,861,711 | +$22,306,675 | 3,015.01% | 7 |
| 2022 Q3 | 115,088 | $3,870,578 | +$1,586,624 | 3,375.59% | 8 |
| 2022 Q2 | 68,935 | $2,146,000 | +$2,146,000 | 3,113.14% | 6 |